Global Bronchiolitis Drugs Market, By Type (Viral Bronchiolitis, Bronchiolitis Obliterans, Others), Treatment (Medication, Oxygen Therapy, Intravenous Fluids, Others), Dosage Form (Injection, Tablets, Others), Route of Administration (Oral, Inhalational, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Bronchiolitis is the most frequent illness of the lower respiratory tract in babies. Lower respiratory tract disease affects 21 percent of North American infants each year, while most infants and young children only get a minor case of bronchiolitis. Bronchitis, on the other hand, affects up to 3% of all children in their first year of life. The respiratory syncytial virus (RSV) is to blame for 70% of all bronchiolitis cases, and for 80% to 100% of cases during the winter months. The remaining instances are mostly caused by parainfluenza, adenovirus, and influenza.
Data Bridge Market Research analyses that the bronchiolitis drugs market was valued at USD 58.62 million in 2021 and is expected to reach USD 83.37 million by 2029, registering a CAGR of 4.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Viral Bronchiolitis, Bronchiolitis Obliterans, Others), Treatment (Medication, Oxygen Therapy, Intravenous Fluids, Others), Dosage Form (Injection, Tablets, Others), Route of Administration (Oral, Inhalational, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Boehringer Ingelheim International GmbH. (Germany), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Allergan (Ireland), Abbott (US), LEO Pharma A/S (Denmark), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (UK), Amneal Pharmaceuticals LLC. (US), Zydus Cadila (India), Akorn, Incorporated (US)
|
|
Market Opportunities
|
|
Market Definition
Bronchiolitis is a recurring lung illness that affects new-borns and small children. It causes inflammation and obstruction in the lungs' tiny airways (bronchioles). It can make you wheeze, cough and have trouble breathing. It occurs when the bronchioles, or small breathing tubes in the lungs, get inflamed. As a result of the mucus clogging the tubes, there isn't enough room for air to get in and out of the lungs. The respiratory syncytial virus (RSV), influenza (flu) viruses and rhinovirus are the most common causes of bronchiolitis.
Bronchiolitis Drugs Market Dynamics
Drivers
- Rise in the prevalence of respiratory syncytial virus (RSV) infection
The surging prevalence of respiratory syncytial virus (RSV) infection is a major factor driving the bronchiolitis drugs market's growth rate. According to the Centers for Disease Control and Prevention (CDC), respiratory syncytial virus (RSV) causes the hospitalization of approximately 1,32,000-172,000 children under the age of five and the death of approximately 14,000 adults over the age of 65 in the United States alone each year. Developing countries account for nearly all RSV-related mortality in children under the age of five. Because respiratory syncytial virus (RSV) infections have clinical signs that are similar to those of other respiratory diseases, there is a rising demand for rapid, specific, and sensitive diagnostic procedures.
- High prevalence rate of smoking
The rise in prevalence rate of smoking will act as a major driver that will result in the expansion of the growth rate of the market. Smoking is one of the causative factor which increases the risk of viral bronchiolitis by raising breathing problems and hence will further cushion the growth rate of bronchiolitis drugs market.
Furthermore, rising initiatives by public and private organizations to spread awareness and rising healthcare expenditure will expand the bronchiolitis drugs market. Additionally, changing lifestyle of people and increasing number of cases of heart diseases and chronic lung disorders will result in the expansion of bronchiolitis drugs market. Along with this, rising incidences of respiratory diseases and increasing number of geriatric population will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the bronchiolitis drugs market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the bronchiolitis drugs market growth during the forecast period.
Restraints/Challenges
On the other hand, expiration of patented drugs and the introduction of generic version of drugs will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and high cost associated with drugs will challenge the bronchiolitis drugs market. Additionally, side effects linked with bronchiolitis drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This bronchiolitis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bronchiolitis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The respiratory syncytial virus causes the majority of viral bronchiolitis cases (RSV). Every autumn and winter, viral outbreaks mostly affect children under the age of two, with infants under the age of six months having the highest risk of serious disease. Bronchitis affects 11 to 15% of new-borns before they become one year old, and hospitalizes roughly 1 in 200 children under the age of two.
Bronchiolitis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Bronchiolitis Drugs Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in a number of nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The lower respiratory tract infection treatment market was hampered by the supply chain slowness. On the bright side, the bronchiolitis drugs market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future.
Recent Development
- In September 2021, Pfizer had announced the start of phase 3 clinical trials in adults for investigational vaccine named RENOIR against respiratory syncytial virus (RSV). The RSVpreF Phase 3 RENOIR trial is a global, randomised, double-blind, placebo-controlled investigation with a target enrollment of 30,000 people aged 60 and up.
Global Bronchiolitis Drugs Market Scope
The bronchiolitis drugs market is segmented on the basis of type, treatment, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Antiviral drugs
- Aerosolized ribavirin
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Intravenous Fluids
- Others
Type
- Viral Bronchiolitis
- Bronchiolitis Obliterans
- Others
Dosage Form
- Injection
- Tablets
- Others
Route of Administration
- Inhalational
- Parenteral
- Oral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Pipeline Analysis
MV130 (Bactek) is being developed by Inmunotek for the treatment of Bronchiolitis. In addition to eliciting specific T cell immunity against the germs present in the preparation, MV130 also demonstrates an increased T cell response to an unrelated flu antigen. TLR and NLR signaling pathways are triggered on DCs, resulting in the release of trained immunity markers.
Bronchiolitis Drugs Market Regional Analysis/Insights
The bronchiolitis drugs market is analysed and market size insights and trends are provided by country, type, treatment, dosage form, route of administration, end-users and distribution channel as referenced above.
The countries covered in the bronchiolitis drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the bronchiolitis drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging prevalence of inflammatory respiratory diseases in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Bronchiolitis Drugs Market Share Analysis
The bronchiolitis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bronchiolitis drugs market.
Some of the major players operating in the bronchiolitis drugs market are:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Allergan (Ireland)
- Abbott (US)
- LEO Pharma A/S (Denmark)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
- Amneal Pharmaceuticals LLC. (US)
- Zydus Cadila (India)
- Akorn, Incorporated (US)
SKU-